

# The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain

NCT04104412

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Schnow Biotechnology Co., Ltd.
Enrollment	242 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- age over 18
  - refractory and persistent lumbago pain for more than 6 months, with/without radiation pain in lower limbs, and poor conservative treatment effect;
  - the straight leg elevation test was 70 degrees negative;
  - MRI of lumbar spine showed herniated disc  $\leq 6$  mm, no obvious compression of spinal cord and nerve roots; T2-weighted mri of the lumbar spine showed decreased single/multi-segment signal (black disc sign) or High signal zone (HIZ) in the posterior part of the intervertebral disc annulus.
  - clinical signs of nerve localization were consistent with MRI changes;
- ... and 1 more (see full listing online)

### Exclusion (12)

- coagulation dysfunction or anticoagulant therapy;
  - intervertebral space infection, puncture site infection or systemic infection;
  - lumbago pain of non-spinal origin, such as sacroiliac joint origin pain;
  - patients who have had open surgery or other disc treatments;
  - imaging examination suggested disc prolapse, prolapse, spinal canal bone stenosis, etc.;
- ... and 7 more (see full listing online)

## Locations (1 total)

---

Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality, China